Welcome to our dedicated page for Ernexa SEC filings (Ticker: ERNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ernexa Therapeutics Inc. (NASDAQ: ERNA) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into Ernexa’s development-stage biotechnology business, which focuses on iPSC-derived iMSC cell therapies for advanced cancer and autoimmune disease.
Through this page, readers can review annual reports on Form 10-K and quarterly reports on Form 10-Q to understand Ernexa’s financial position, operating expenses, research and development priorities, and risk disclosures typical of early-stage biotechnology companies. Current reports on Form 8-K capture material events, such as the disclosed change in Ernexa’s independent registered public accounting firm and references to going concern considerations and internal control matters.
For those following governance and ownership, proxy statements and related filings can provide information on board structure and executive compensation, while beneficial ownership reports and Form 4 filings allow tracking of insider transactions by directors, officers, and significant shareholders, when available. Together, these documents help investors and analysts evaluate how Ernexa manages its cell therapy programs, capital resources, and corporate oversight.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, explain complex sections in plain language, and draw attention to items such as going concern notes, material weaknesses in internal control, or important changes in auditors. Real-time updates from EDGAR ensure that new Ernexa filings appear promptly, while AI-generated overviews of 10-Ks, 10-Qs, 8-Ks, and Form 4 submissions can save time for users seeking to understand the regulatory record behind the ERNA ticker.
Ernexa Therapeutics Inc. insider and 10% owner Cherington Charles bought 4,000,000 shares of common stock on February 10, 2026, in a follow-on offering pursuant to a prospectus supplement dated February 6, 2026. The combined purchase price per share of common stock and accompanying warrant was $0.50.
At the same time, Cherington Charles acquired 4,000,000 warrants to purchase common stock. These warrants will expire on the earlier of February 10, 2031 or the 180th calendar day following the public release of clinical trial data from the first cohort of the Phase 1 study of ERNA-101.
Ernexa Therapeutics Inc. entered into agreements for a best-efforts public offering of common stock and warrants, raising approximately $10.5 million in gross proceeds. The deal covers 21,000,000 shares of common stock (or equivalents) and warrants to purchase up to 21,000,000 shares, at a combined price of $0.50 per share (or equivalent) and warrant.
The warrants are immediately exercisable at $0.68 per share and will expire on the earlier of five years from issuance or 180 days after the first-cohort Phase 1 ERNA-101 data release. Pre-funded warrants for 2,000,000 shares carry a $0.01 exercise price. The Nasdaq-listed warrants trade under the symbol ERNAW.
Brookline Capital Markets, a division of Arcadia Securities, acted as placement agent, earning cash fees and 231,576 shares as compensation. Ernexa plans to use net proceeds to advance its cell therapy programs, working capital, and general corporate purposes, and has agreed to 90-day issuance restrictions and officer/director lock-ups.
Ernexa Therapeutics Inc. is conducting a reasonable best-efforts public offering of 21,000,000 shares of common stock (or pre-funded warrants in lieu thereof), each paired with a Common Warrant to purchase one share, plus 231,576 Agent’s Shares as compensation to the placement agent. The combined public offering price is $0.50 per share of Common Stock and accompanying Common Warrant, and $0.49 per pre-funded warrant and accompanying Common Warrant, for total gross proceeds of $10,480,000.00 and estimated proceeds before expenses of $10,007,360.00. The Common Warrants have a $0.68 exercise price, are immediately exercisable, and may expire as early as 180 days after public release of first-cohort Phase 1 ERNA-101 data. This is a no-minimum, best-efforts deal, so the company may raise less than the full amount, and investors will not receive refunds. Ernexa is a preclinical synthetic iMSC therapy company that discloses it will not have sufficient capital to fund operations for 12 months without additional financing and highlights substantial ongoing losses and significant business and regulatory risks.
Ernexa Therapeutics Inc. is registering up to 13,586,956 shares of common stock, associated pre-funded warrants and common warrants, plus up to 203,804 Agent’s Shares, in a primary, best-efforts offering with no minimum amount required to close.
Each common share is sold together with a common warrant to buy one additional share, at a combined price assumed at $0.92, the February 3, 2026 Nasdaq closing price. Certain large investors may instead buy pre-funded warrants priced $0.005 below the share price, with a $0.005 exercise price and no expiration until fully exercised.
The common warrants will be immediately exercisable, with an exercise price set at the Nasdaq closing price at pricing, and will expire on the earlier of five years from issuance or 180 days after public release of first-cohort Phase 1 data for ERNA-101. Common stock trades on Nasdaq as “ERNA,” and Ernexa has applied to list the common warrants as “ERNAW.”
The company highlights significant ongoing losses, a large accumulated deficit and a need for substantial additional capital, warning it may not be able to continue as a going concern without new funding. It also discloses heavy reliance on licensed intellectual property from Factor Bioscience and outlines extensive business, technology, regulatory, and offering-related risks, including potentially significant dilution and the absence of any dividend plan.
Ernexa Therapeutics Inc. is seeking to raise up to $12,500,000 through a best-efforts public offering of common stock and common warrants, with Brookline Capital Markets acting as exclusive placement agent. Each share is sold with a warrant to buy one additional share, and the warrants are expected to list on Nasdaq as “ERNAW.”
The company is a preclinical-stage developer of synthetic iMSC cell therapies, led by ERNA-101 for platinum-resistant ovarian cancer, with an IND filing targeted in 2026 and a Phase 1 trial planned thereafter. Ernexa recently increased its authorized common stock to 150 million shares, executed a 1-for-15 reverse split, and raised about $7.2 million in a prior private placement, yet still warns it will require substantial additional capital and faces going-concern, regulatory, competition, intellectual property, and Nasdaq listing risks.
Ernexa Therapeutics Inc. has filed an S-1 for a primary, best-efforts offering of common stock paired with tradable common warrants, with Brookline Capital Markets acting as exclusive placement agent. The company will also issue “Agent’s Shares” equal to 1.5% of shares sold (0.5% for certain existing investors).
The warrants are immediately exercisable at a price based on the Nasdaq closing price at pricing and will expire on the earlier of five years from issuance or 180 days after public release of first-cohort Phase 1 ERNA-101 data. Ernexa is a preclinical synthetic iMSC cell-therapy company focused on ERNA-101 in platinum-resistant ovarian cancer and ERNA-201 for autoimmune disease.
Recent actions include increasing authorized common stock to 150 million shares, a 1-for-15 reverse split, and a $7.2 million 2025 private placement. As of January 27, 2026, 7,853,538 common shares were outstanding. The risk section highlights substantial additional capital needs, going concern risk, dependence on licensed IP, intense competition, and potential Nasdaq listing and dilution risks.
Ernexa Therapeutics Inc. reported Q3 2025 results with a net loss of $1.24 million, a sharp improvement from a loss of $26.60 million a year ago. Year‑to‑date net loss was $12.58 million versus $38.78 million in 2024. There was no revenue in Q3 2025, compared with $0.49 million in Q3 2024, reflecting the prior assignment of its customer contract to Factor Bioscience.
Operating expenses were stable to lower: research and development was $1.04 million (vs. $1.00 million), while general and administrative fell to $0.96 million (vs. $3.38 million), aided by the absence of prior-year lease and professional fee items. Other income included a $0.73 million gain from writing off time‑barred payables. Year‑to‑date other expense was driven by a $5.85 million non‑cash forward sales contract expense tied to a 2025 private placement.
Cash was $3.05 million as of September 30, 2025, up from $1.73 million at year‑end, after $7.20 million of gross proceeds from common stock and pre‑funded warrant sales in 2025 and repayment of $2.3 million promissory notes. The company used $5.87 million in operating cash year‑to‑date and states there is substantial doubt about its ability to continue as a going concern without additional capital. A 1‑for‑15 reverse stock split became effective on June 12, 2025; 7,848,889 common shares were outstanding as of November 7, 2025.
IAF, LLC reports it currently beneficially owns 315,779 shares of Ernexa Therapeutics Inc. common stock, representing 4.1% of the outstanding class based on 7,670,889 shares reported by the issuer. This Amendment No. 3 updates prior Schedule 13G filings and indicates the reporting person has ceased to own more than 5% of the company, making this an "exit filing." The filing shows all 315,779 shares are held with sole voting and sole dispositive power and confirms the holder does not report ownership on behalf of others or as part of a group.
Ernexa Therapeutics is a preclinical synthetic allogeneic iMSC therapy company developing ERNA-101 (IL-7/IL-15–secreting) for oncology and ERNA-201 for inflammatory disorders. Management expects to complete IND-enabling studies and submit an IND in 2026 with a planned Phase I investigator-sponsored trial in the second half of 2026.
Financially, the company reported $4.3 million in cash and an accumulated deficit of $242.9 million. Net loss was $3.1 million for the quarter and $11.3 million for the six months, which includes a $5.8 million non-cash forward sales contract expense. Ernexa raised approximately $7.2 million gross from a private placement, completed a 1-for-15 reverse stock split and increased authorized common shares to 150 million. Management disclosed substantial doubt aboutgoing concern and stated additional financing will be required. Stockholders' equity was $4.4 million at period end and the company reports compliance with Nasdaq continued listing standards.